We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

197 hedge funds and large institutions have $1.33B invested in Ligand Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 60 increasing their positions, 76 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

464% more call options, than puts

Call options by funds: $4.73M | Put options by funds: $839K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

5% less funds holding

Funds holding: 208 → 197 (-11)

7.31% less ownership

Funds ownership: 148.76% → 141.45% (-7.3%)

20% less capital invested

Capital invested by funds: $1.67B → $1.33B (-$341M)

21% less repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 76

29% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 24

Holders
197
Holders Change
-11
Holders Change %
-5.29%
% of All Funds
3.32%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
17
Increased
60
Reduced
76
Closed
24
Calls
$4.73M
Puts
$839K
Net Calls
+$3.89M
Net Calls Change
+$121K

Top Buyers

1
Aberdeen Group
Aberdeen Group
United Kingdom
+$8.51M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$5.88M
3
Pacer Advisors
Pacer Advisors
Pennsylvania
+$5.29M
4
MPAM
Monarch Partners Asset Management
Massachusetts
+$4.24M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.21M

Top Sellers

1
William Blair Investment Management
William Blair Investment Management
Illinois
-$47.1M
2
SCM
Snyder Capital Management
California
-$16.9M
3
KCM
Kornitzer Capital Management
Kansas
-$7.55M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.51M
5
Millennium Management
Millennium Management
New York
-$4.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
M&T Bank
201
M&T Bank
New York
– -$397K -5,647 Closed
FI
202
Fosun International
China
– -$349K -4,809 Closed
Walleye Trading
203
Walleye Trading
New York
– -$260K -3,706 Closed
PAM
204
Paradigm Asset Management
New York
– -$236K -3,366 Closed
SACTSONJ
205
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
– -$214K -3,046 Closed
RIM
206
Redwood Investment Management
Arizona
– -$213K -3,030 Closed
Citadel Advisors
207
Citadel Advisors
Florida
– -$169K -2,982 Closed
CWP
208
Concord Wealth Partners
Virginia
– -$14K -247 -98%
First Manhattan
209
First Manhattan
New York
– -$11K -160 Closed
PFS
210
Prospera Financial Services
Texas
– -$4K -64 Closed
GAM
211
Gemmer Asset Management
California
– -$3K -45 Closed
EC
212
Elequin Capital
New York
– -$1K -14 Closed
TSWM
213
Tyler-Stone Wealth Management
Ohio
– -$1K -8 Closed
JWA
214
JFS Wealth Advisors
Pennsylvania
– -$284 -5 -63%
SFG
215
Steward Financial Group
Texas
– +$284 +5 New
5 6 7 8
9

LGND Hedge Fund Activity: Q2 2022 in Review

197 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2022, worth a combined $1.33B — down 20% from $1.67B a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of LGND and 17 opened new positions — a net loss of 7 holders — while 76 trimmed existing stakes and 60 added.

The largest buyer was Aberdeen Group, adding an estimated $8.51M. The largest seller was William Blair Investment Management, cutting an estimated $47.1M.

  • 197 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2022, down from 208 in Q1 2022.
  • Funds reported $1.33B of Ligand Pharmaceuticals stock for Q2 2022, down 20% quarter-over-quarter.
  • 17 funds opened new Ligand Pharmaceuticals positions in Q2 2022 and 24 closed out, a net change of -7 holders.
  • The largest Ligand Pharmaceuticals buyer in Q2 2022 was Aberdeen Group, an estimated $8.51M added.
  • The largest Ligand Pharmaceuticals seller in Q2 2022 was William Blair Investment Management, an estimated $47.1M sold.

Based on aggregated 13F filings for Q2 2022.